ELPA’S VISION OF SCREENING

By Nadine Piorkowsky

President of the

European Liver Patients Association,

Budapest, 18-19 March 2010
ELPA’s network
The Patient’s View

• a viral time bomb: Up to 9 out of 10 chronic hepatitis carriers are unaware of their infection

• Patients have a right to know that they are infected: This way,
  ➢ they can receive treatment and their disease can be controlled or cured
  ➢ they can prevent further transmission
ELPA’s vision of screening

Two-fold approach:

• direct outreach to risk groups tailored and targeted to their needs

• promoting hepatitis-awareness amongst primary care professionals

→ Increase number of diagnosed patients
EU policy activities to promote screening

Overarching goal:

Council Recommendation on Hepatitis B and C

Important steps:

• Written Declaration on Hepatitis C

• EASL/ELPA Expert Recommendations
Which Risk Groups to target

The definition of high risk groups is an essential tool in designing targeted screening programmes for viral hepatitis.

<table>
<thead>
<tr>
<th>High risk groups for Hepatitis B include:</th>
<th>High risk groups for Hepatitis C include</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Persons with elevated liver enzymes and/or clinical sign of hepatitis</td>
<td>• Persons with elevated liver enzymes and/or symptoms of hepatitis</td>
</tr>
<tr>
<td>• Patients with liver cirrhosis or fibrosis</td>
<td>• Patients with liver cirrhosis or fibrosis</td>
</tr>
<tr>
<td>• Patients with hepatocellular carcinoma</td>
<td>• People who share or have ever shared needles (injecting drug users)</td>
</tr>
<tr>
<td>• People who share or have ever shared needles (injecting drug users)</td>
<td>• People with long-term imprisonment history</td>
</tr>
<tr>
<td>• People with long-term imprisonment history</td>
<td>• People who are undergoing or have undertaken hemodialysis</td>
</tr>
<tr>
<td>• People who are undergoing or have undertaken hemodialysis</td>
<td>• People who have received repeated percutaneous injections</td>
</tr>
<tr>
<td>• Men who have sew with men or heterosexual persons with multiple sex partners</td>
<td>• People who have had invasive medical and paramedical or dental work</td>
</tr>
<tr>
<td>• People with HIV or HCV infection</td>
<td>in countries with high prevalence or poor sterilisation procedures, such</td>
</tr>
<tr>
<td>• Families and household members or sexual partners of persons infected with HBV</td>
<td>as use of multidose vials</td>
</tr>
<tr>
<td>Patients and staff in psychiatric institutions or residents of welfare institutions for mentally disabled</td>
<td>• People who received blood transfusions or other blood derived products</td>
</tr>
<tr>
<td>persons</td>
<td>outside the EU or before 1992 in the EU</td>
</tr>
<tr>
<td>• Pregnant women and newborns of HBV-infected mothers</td>
<td>• People who received organs and tissues transplants outside the EU or before 1992 in the EU</td>
</tr>
<tr>
<td>• Recipients of organ transplants and blood products</td>
<td>• Haemophiliacs who received concentrated coagulation factors before</td>
</tr>
<tr>
<td>• Blood and organ donors</td>
<td>1987</td>
</tr>
<tr>
<td>• Patients before or during immunosuppressive treatment or chemotherapy</td>
<td>• People with HIV infection</td>
</tr>
<tr>
<td>• Migrants from countries with high prevalence of Hepatitis B</td>
<td>• People who have used intra-nasal cocaine</td>
</tr>
<tr>
<td>• Unvaccinated healthcare workers and public safety workers who undertake exposure-prone procedures.</td>
<td>• People with body piercings if being performed in non hygienic environments</td>
</tr>
<tr>
<td></td>
<td>• Children of HCV-infected mothers</td>
</tr>
<tr>
<td></td>
<td>• Healthcare workers and public safety workers who undertake exposure-prone procedures.</td>
</tr>
</tbody>
</table>
ELPA in the Cancer Partnership

• More than 75% of liver cancer are attributable to a prior Hepatitis infection.
• Liver cancer is one of few tumour types with rising incidence
• Partnership: Focus on Cancer Prevention
• ELPA’s goals:
  – liver cancer specifically acknowledged by the partnership
  – Hepatitis prevention (primary and secondary) should be recognised as important means to prevent liver cancer.
Patients need drugs and data to feel better

- Urgent need for reliable and comparable data across the EU
  - demonstrate the burden of the disease
  - establish risk-group specific screening as a cost-effective way to help curb this burden
Thank you!

Nadine Piorkowsky, President of ELPA

http://www.elpa-info.org
elpa-president@t-online.de